- Home
- IONS
as 07-26-2024 4:00pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 7.0B | IPO Year: | 1991 |
| Target Price: | $61.29 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.95 - $54.44 | Next Earning Date: | 08-07-2024 |
| Revenue: | $776,620,000 | Revenue Growth: | 34.84% |
| Revenue Growth (this year): | -21.67% | Revenue Growth (next year): | 26.99% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KLEIN JOSEPH III | IONS | Director | Jul 16 '24 | Sell | $50.00 | 12,000 | $600,000.00 | 0 | SEC Form 4 |
| BERTHELSEN SPENCER R | IONS | Director | Jun 17 '24 | Sell | $40.29 | 16,000 | $644,640.00 | 147,257 | SEC Form 4 |
| KLEIN JOSEPH III | IONS | Director | May 3 '24 | Sell | $42.57 | 1,318 | $56,110.03 | 4,682 | SEC Form 4 |
| KLEIN JOSEPH III | IONS | Director | May 3 '24 | Sell | $42.94 | 682 | $29,288.42 | 4,000 | SEC Form 4 |
| KLEIN JOSEPH III | IONS | Director | May 3 '24 | Sell | $42.59 | 1,269 | $54,043.54 | 2,731 | SEC Form 4 |
| KLEIN JOSEPH III | IONS | Director | May 3 '24 | Sell | $42.98 | 731 | $31,415.97 | 2,000 | SEC Form 4 |
| KLEIN JOSEPH III | IONS | Director | May 3 '24 | Sell | $42.55 | 1,070 | $45,525.61 | 930 | SEC Form 4 |
| KLEIN JOSEPH III | IONS | Director | May 3 '24 | Sell | $42.90 | 930 | $39,893.00 | 0 | SEC Form 4 |
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Apr 15 '24 | Sell | $41.60 | 4,006 | $166,640.79 | 19,631 | SEC Form 4 |
| Birchler Brian | IONS | EVP, Corp and Development Ops | Apr 15 '24 | Sell | $41.66 | 905 | $37,698.23 | 46,156 | SEC Form 4 |
| Monia Brett P | IONS | Chief Executive Officer | Feb 16 '24 | Sell | $44.49 | 387 | $17,218.56 | 173,751 | SEC Form 4 |
| Schneider Eugene | IONS | EVP, Chf Clinical Develop Ofcr | Feb 1 '24 | Sell | $49.59 | 2,071 | $102,700.89 | 49,812 | SEC Form 4 |
| BENNETT C FRANK | IONS | EVP, Chief Scientific Officer | Feb 1 '24 | Sell | $49.52 | 1,853 | $91,752.41 | 79,079 | SEC Form 4 |
| Monia Brett P | IONS | Chief Executive Officer | Feb 1 '24 | Sell | $49.37 | 23,501 | $1,160,303.12 | 174,138 | SEC Form 4 |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Feb 1 '24 | Sell | $49.67 | 1,961 | $97,410.32 | 48,661 | SEC Form 4 |
| HOUGEN ELIZABETH L | IONS | EVP, Finance & CFO | Feb 1 '24 | Sell | $49.54 | 2,125 | $105,272.29 | 92,905 | SEC Form 4 |
| Geary Richard S | IONS | EVP, Chief Development Officer | Feb 1 '24 | Sell | $50.04 | 1,961 | $98,134.91 | 87,334 | SEC Form 4 |
| Cadoret-Manier Onaiza | IONS | EVP, Chf GL Pdt Str & Oper Ofc | Feb 1 '24 | Sell | $49.60 | 2,125 | $105,404.25 | 35,825 | SEC Form 4 |
| Swayze Eric | IONS | EVP Research | Jan 31 '24 | Sell | $52.00 | 10,773 | $560,196.00 | 32,516 | SEC Form 4 |
| Swayze Eric | IONS | EVP Research | Jan 31 '24 | Sell | $49.56 | 1,907 | $94,513.40 | 34,324 | SEC Form 4 |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Jan 25 '24 | Sell | $51.75 | 6,450 | $333,787.50 | 46,802 | SEC Form 4 |
| Monia Brett P | IONS | Chief Executive Officer | Jan 25 '24 | Sell | $51.75 | 2,285 | $118,248.75 | 151,851 | SEC Form 4 |
| Cadoret-Manier Onaiza | IONS | EVP, Chf GL Pdt Str & Oper Ofc | Jan 16 '24 | Sell | $50.42 | 5,564 | $280,520.19 | 33,810 | SEC Form 4 |
| Birchler Brian | IONS | EVP, Corp and Development Ops | Jan 16 '24 | Sell | $50.42 | 4,497 | $226,725.25 | 44,582 | SEC Form 4 |
| Geary Richard S | IONS | EVP, Chief Development Officer | Jan 16 '24 | Sell | $50.42 | 7,338 | $369,959.95 | 85,475 | SEC Form 4 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
MT Newswires
3 days ago
Leerink Partners Upgrades Ionis Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $62 From $53
Zacks
3 days ago
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
Clinical Trials Arena
4 days ago
Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug
Investor's Business Daily
4 days ago
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
MT Newswires
4 days ago
Sector Update: Health Care Stocks Higher Monday Afternoon
MT Newswires
4 days ago
Ionis Pharmaceuticals Shares Rise After Positive Results for Angelman Syndrome Drug Study
BioPharma Dive
4 days ago
Ionis plots next steps for Angelman drug Biogen passed on
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.